Tricia Suvari Net Worth

The estimated Net Worth of Tricia Borga Suvari is at least $7.68 Milhão dollars as of 1 September 2022. Ms. Suvari owns over 4,971 units of Global Blood Therapeutics stock worth over $3,079,173 and over the last 8 years she sold GBT stock worth over $958,957. In addition, she makes $3,640,440 as Chief Legal Officer at Global Blood Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Suvari GBT stock SEC Form 4 insiders trading

Tricia has made over 15 trades of the Global Blood Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 4,971 units of GBT stock worth $340,464 on 1 September 2022.

The largest trade she's ever made was exercising 9,395 units of Global Blood Therapeutics stock on 1 February 2022 worth over $643,464. On average, Tricia trades about 2,793 units every 37 days since 2016. As of 1 September 2022 she still owns at least 44,958 units of Global Blood Therapeutics stock.

You can see the complete history of Ms. Suvari stock trades at the bottom of the page.

Tricia Suvari biography

Tricia Borga Suvari Esq. serves as Chief Legal Officer of the Company. From 2000 until 2009, Ms. Suvari served in several senior roles at CV Therapeutics, Inc., a biopharmaceutical company (acquired by Gilead Sciences, Inc. in 2009), ultimately as senior vice president, general counsel and chief compliance officer. Prior to CV Therapeutics, from 1991 until 2000, she served as corporate counsel at Genentech, Inc., in increasingly senior roles. From February 2012 until July 2016, Ms. Suvari served as a vice president and general counsel at the non-profit Peninsula Open Space Trust, and from early 2011 to February 2012 she served as an independent consultant to biopharmaceutical companies. Ms. Suvari earned her Bachelor of Sciences degree in Geology and Geophysics from Yale University and her J.D. degree from Harvard Law School.

What is the salary of Tricia Suvari?

As the Chief Legal Officer of Global Blood Therapeutics, the total compensation of Tricia Suvari at Global Blood Therapeutics is $3,640,440. There are 2 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.

How old is Tricia Suvari?

Tricia Suvari is 59, she's been the Chief Legal Officer of Global Blood Therapeutics since 2016. There are 12 older and 8 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.

What's Tricia Suvari's mailing address?

Tricia's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Global Blood Therapeutics

Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., eKevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.

What does Global Blood Therapeutics do?

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

Complete history of Ms. Suvari stock trades at Global Blood Therapeutics

Global Blood Therapeutics executives and stock owners

Global Blood Therapeutics executives and other stock owners filed with the SEC include:

• Ted Love,
  President, Chief Executive Officer, Director
• Brian Cathers,
  Chief Scientific Officer
• Tricia Suvari,
  Chief Legal Officer
• Jung Choi,
  Chief Business and Strategy Officer
• David Johnson,
  Chief Commercial Officer
• Jeffrey Farrow,
  Chief Financial Officer
• Dr. Ted W. Love,
  Pres, CEO & Director
• Dr. Ted W. Love M.D.,
  Pres, CEO & Director
• David L. Johnson,
  Chief Commercial Officer
• Jeffrey S. Farrow,
  CFO & Principal Accounting Officer
• Jung E. Choi,
  Chief Bus. & Strategy Officer
• Dr. Kim Smith-Whitley M.D.,
  Exec. VP and Head of R&D
• Patricia Borga Suvari,
  Chief Legal Officer & Sec.
• Mark Perry,
  Lead Independent Director
• Scott Morrison,
  Independent Director
• Wendy Yarno,
  Independent Director
• Deval Patrick,
  Director
• Glenn Pierce,
  Independent Director
• Philip Pizzo,
  Independent Director
• Willie Brown,
  Independent Director
• Dawn Svoronos,
  Independent Director
• Eric Fink,
  Chief Human Resource Officer
• Stephanie Yao,
  Sr. Director of Corp. Communications & Investor Relations
• Nazila Habibizad,
  Exec. VP of Operations
• Dr. Andrej Sali Ph.D.,
  Founder & Advisor
• Dr. Matthew P. Jacobson Ph.D.,
  Founder & Advisor
• Dr. David R. Phillips,
  Founder & Advisor
• Lesley Ann Calhoun,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Ii, L.P.Third...,
  
• Michael W Bonney,
  Director
• Eleanor Ramos,
  Chief Medical Officer
• Kevin P Starr,
  Director
• Charles J Homcy,
  Director
• Robert I Tepper,
  10% owner
• Rock Ventures Ii, L.P.Starr...,
  
• Hing Sham,
  See Remarks
• Joshua Lehrer Graiwer,
  Chief Medical Officer
• Advisors Llcperceptive Life...,
  
• Peter Radovich,
  See Remarks
• Nazila Habibizad,
  See Remarks
• John Schembri,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Carrie Krehlik,
  Chief Human Resources Officer
• Alexis A. Thompson,
  Director
• Kim Smith Whitley,
  See Remarks